Cullinan Total Operating Expenses vs Reconciled Depreciation Analysis
| CGEM Stock | USD 12.22 0.36 2.86% |
Cullinan Oncology financial indicator trend analysis is way more than just evaluating Cullinan Oncology LLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cullinan Oncology LLC is a good investment. Please check the relationship between Cullinan Oncology Total Operating Expenses and its Reconciled Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Total Operating Expenses vs Reconciled Depreciation
Total Operating Expenses vs Reconciled Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cullinan Oncology LLC Total Operating Expenses account and Reconciled Depreciation. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Cullinan Oncology's Total Operating Expenses and Reconciled Depreciation is 0.9. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Cullinan Oncology LLC, assuming nothing else is changed. The correlation between historical values of Cullinan Oncology's Total Operating Expenses and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Cullinan Oncology LLC are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Total Operating Expenses i.e., Cullinan Oncology's Total Operating Expenses and Reconciled Depreciation go up and down completely randomly.
Correlation Coefficient | 0.9 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Reconciled Depreciation
Most indicators from Cullinan Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cullinan Oncology LLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. As of the 22nd of November 2024, Selling General Administrative is likely to grow to about 44.6 M, though Tax Provision is likely to grow to (13.4 M).
| 2023 | 2024 (projected) | Non Recurring | 183.9K | 97.2K | Research Development | 148.2M | 155.6M |
Cullinan Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Cullinan Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cullinan Oncology fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 100.5M | 214.7M | 437.2M | 561.1M | 484.2M | 508.4M | |
| Total Current Liabilities | 2.5M | 14.3M | 11.7M | 22.5M | 28.1M | 29.5M | |
| Accounts Payable | 934K | 9.7M | 3.2M | 2.7M | 2.5M | 2.0M | |
| Other Current Assets | 1.5M | 4.1M | 12.2M | 7.2M | 13.1M | 13.8M | |
| Total Liab | 140.4M | 291.0M | 11.8M | 26.1M | 30.3M | 55.9M | |
| Total Stockholder Equity | (40.8M) | (77.6M) | 422.6M | 535.0M | 453.7M | 476.4M | |
| Net Tangible Assets | (40.8M) | (77.6M) | 425.0M | 535.0M | 615.3M | 646.0M | |
| Retained Earnings | (41.5M) | (93.3M) | (158.9M) | (47.7M) | (200.9M) | (190.8M) | |
| Cash | 63.3M | 168.2M | 430.9M | 550.1M | 98.4M | 147.9M | |
| Total Current Assets | 100.1M | 212.3M | 296.6M | 474.5M | 480.2M | 504.2M | |
| Other Current Liab | 1.6M | 4.6M | 8.6M | 14.0M | 22.8M | 23.9M | |
| Property Plant And Equipment Net | 182K | 130K | 77K | 5.3M | 3.5M | 3.7M | |
| Net Debt | (63.3M) | (168.2M) | (430.9M) | (544.9M) | (94.8M) | (99.6M) | |
| Non Current Assets Total | 370K | 2.4M | 140.6M | 86.6M | 4.0M | 3.8M | |
| Cash And Short Term Investments | 98.6M | 210.2M | 430.9M | 550.1M | 467.1M | 328.3M | |
| Short Term Investments | 35.4M | 42.0M | 230.7M | 311.1M | 368.6M | 387.1M | |
| Liabilities And Stockholders Equity | 100.5M | 214.7M | 434.8M | 561.1M | 484.2M | 335.5M | |
| Non Current Liabilities Total | 137.8M | 276.7M | 65K | 3.6M | 2.2M | 2.0M | |
| Other Stockholder Equity | (137.0M) | 15.7M | 584.7M | 585.3M | 654.7M | 687.4M | |
| Net Invested Capital | (40.8M) | (77.6M) | 425.0M | 535.2M | 453.7M | 233.7M | |
| Property Plant And Equipment Gross | 182K | 130K | 309K | 5.4M | 3.9M | 4.1M | |
| Accumulated Other Comprehensive Income | (4K) | (2K) | (838K) | (2.6M) | (129K) | (135.5K) | |
| Net Working Capital | 97.6M | 198.0M | 284.8M | 452.0M | 452.1M | 278.2M | |
| Property Plant Equipment | 182K | 130K | 77K | 1.2M | 1.4M | 1.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.